HomeProductsBuilding BlocksHeterocyclic ScaffoldsPyrrolidinesAbt-510
Chemical structure of CAS 251579-55-2

Abt-510

CAS No.251579-55-2
MDL No.N/A
MFC46H83N13O11
MW994.20
InChI KeyRIWLPSIAFBLILR-WVNGMBSFSA-N
CUSTOM SYNTHESISPRECLINICAL SUPPORT

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.251579-55-2
Product NameAbt-510

Associated Conditions

Hodgkins lymphoma·non-small cell lung carcinoma·neoplasm·cutaneous melanoma·sarcoma·
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors.

Annals of oncology : official journal of the European Society for Medical Oncology • Vol. 17, Issue 8 • 2006
PMID: 16728485DOI: 10.1093/annonc/mdl102

Preclinical evaluation of antiangiogenic thrombospondin-1 peptide mimetics, ABT-526 and ABT-510, in companion dogs with naturally occurring cancers.

Clinical cancer research : an official journal of the American Association for Cancer Research • Vol. 12, Issue 24 • 2006
PMID: 17189418DOI: 10.1158/1078-0432.CCR-06-0109

Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy.

Clinical cancer research : an official journal of the American Association for Cancer Research • Vol. 11, Issue 18 • 2005
PMID: 16166447DOI: 10.1158/1078-0432.CCR-05-0621

Documentation

Similar Products